Skip to main content

Advertisement

Table 1 Reported cases of pseudomyogenic hemangioendothelioma

From: Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma

References Cases (N) Sex Tumor location Multifocality at diagnosis Management
Sheng [1] 1 Male: 100 % (1of 1) Female: 0 % (0 of 1) Extremity: 100 % (1 of 1) 100 % (1 of 1) Excision: 100 % (1 of 1)
Hornick and Fletcher [2] 50 Male: 82 % (41 of 50) Female: 18 % (9 of 50) Extremity: 78 % (39 of 50) Trunk: 18 % (9 of 50) Head and neck: 4 % (2 of 50) 66 % (33 of 50) Excision: 92 % (46 of 50) Post-operative radiation: 16 % (8 of 50) Chemotherapy: 12 % (6 of 50)
Amary et al. [5] 5 (1 case included in Hornick was excluded)a Male: 50 % (2 of 4) Female: 50 % (2 of 4) Extremity: 100 % (4 of 4) 75 % (3 of 4) Excision: 75 % (3of 4) Chemotherapy: 25 % (1 of 4)
Stuart et al. [7] 1 Male: 100 % (1 of 1) Female: 0 % (0 of 1) Extremity: 100 % (1 of 1) 100 % (1 of 1) Chemotherapy: 100 % (1 of 1)
Sheng and Wang [9] 1 Male: 0 % (0 of 1) Female: 100 % (1 of 1) Extremity: 100 % (1 of 1) 100 % (1 of 1) Excision: 100 % (1 of 1)
Requena et al. [10] 2 Male: 50 % (1 of 2) Female: 50 % (1 of 2) Extremity: 50 % (1 of 2) Head and neck: 50 % (1 of 2) 100 % (2 of 2) Excision: 100 % (2 of 2)
Righi [11] 2 Male: 50 % (1 of 2) Female: 50 % (1 of 2) Extremity: 100 % (2 of 2) 100 % (2 of 2) Excision: 100 % (2 of 2)
Karakasli et al. [12] 1 Male: 100 % (1 of 1) Extremity: 100 % (1 of 1) 0 % (0 of 1) Excision: 100 % (1 of 1)
McGinity [13] 1 Male: 100 % (1 of 1) Female: 0 % (0 of 1) Extremity: 0 % (0 of 1) Trunk: 100 % (1 of 1) 0 % (0 of 1) Excision: 100 % (1 of 1)
Total 63 Male: 78 % (49 of 63) Female: 22 % (14 of 63) Extremity: 79 % (50 of 63) Trunk: 16 % (10 of 63) Head and neck: 5 % (3 of 63) Multifocality at diagnosis: 68 % (43 of 63) Excision: 90 % (57 of 63) Post-op radiation: 13 % (8 of 63) Chemotherapy: 13 % (8 of 63)
  1. aPatient 5 of this report was already accounted for in the series by Hornick et al. [2]